Abstract: Background: Gabapentin and pregabalin inhibit Ca 2+ currents via high-voltage-activated channels containing the 2 -1 subunit, reducing neurotransmitter release and attenuating the postsynaptic excitability. They are antiepileptic drugs successfully used also for the chronic pain treatment. A large number of clinical trials indicate that gabapentin and pregabalin could be effective as postoperative analgesics. This systematic-narrative review aims to analyse the most recent evidences regarding the effect of gabapentinoids on postoperative pain treatment.
INTRODUCTION
Gabapentin (GBP) [1-(aminomethyl) cyclohexaneacetic acid] -an alkylated analogue of gammaaminobutyric acid (GABA) was introduced in 1993 in Europe and the following year in USA. It was first developed as an anticonvulsant drug and than the GBP potentials as an analgesic drug for the treatment of the neuropathic pain was described in mid 1990s [1, 2] 
. Pregabalin (PGL) [(S)-(+)-3-(aminomethyl)-5-methylhexanoic acid] was indroduced in
Europe and USA a decade after the GBP approval and has a similar pharmacological alkylated GABA analogue structure.
Pharmacology
Similar, in few pharmacological aspects but, different in others, both GBP and PGL produce several pharmacological K v 7/KCNQ/M -K + channels that mediate the M-current, which acts a brake on repetitive firing and burst generation [16] . Activation of GABA B receptor by GBP is almost controversial [17] [18] [19] , meanwhile no evidence of interaction with GABA B receptor is reported for PGL [20] . Inhibitory modulation of PGL is also exerted in neocortex, amygdale e hippocampus [21] . A summery of GBP and PGL similarities and differences on mechanisms of action, pharmacokinetics, interactions with other drugs, uses, dosage and side effects is reported in Table 1 .
Gabapentinoids Indication for Use
These anticonvulsants have been used for the treatments of a wide variety of disorders including general tonic-clonic seizure, partial seizures, peripheral neuropathic pain, diabetic peripheral neuropathy, post-herpetic neuralgia and acute pain [22] . Furthermore, GBP and PGL seem to be effective on various forms of pruritus, including uraemic pruritus, intractable hiccups and hot flushes in post-menopausal women [23] . With respect to the GBP benefits on phantom 
Mechanisms of action
• Interaction with L-amino acid transporter (important for absorption from gastrointestinal tract and distribution across blood-brain barrier) [3, 4] • Activation of GABAB receptor (controverse) [17] [18] [19] • Inhibition of Ca 2+ currents via high-voltage-activated channels containing the 2 -1 subunit, reducing neurotransmitter release and attenuation of postsynaptic excitability [5] [6] [7] [8] [9] [10] . The decreased Ca 2+ influx reduces also the excitatory aminoacid (ex: glutamate) and substance P release, leading to suppression of neuronal excitability after nerve or tissue injury [11] and decrease AMPA receptor activation and noradrenaline release in the brain [97] . Interaction with spinal -2-adrenergic receptor systems in the rat, and GBP administration reduces cerebrospinal fluid norepinephrine levels in humans [13] .
• GBP exerts its analgesic action through a negative indirect interaction with the glycine binding site of NMDA receptors [14, 15] .
• SV2A, a ubiquitous synaptic vesicle glycoprotein that may prepare vesicles for fusion and serves as the target for levetiracetam and its analogue brivaracetam (which is currently in late-stage clinical development) [16] .
• Kv7/KCNQ/M -K + channels that mediate the M-current, which acts a brake on repetitive firing and burst generation [16] .
• Interaction with L-amino acid transporter (important for absorption from g.i. tract and distribution across blood-brain barrier) [3, 4] • No evidence of interaction with GABAB receptor [20] • Inhibition of Ca 2+ currents via high-voltageactivated channels containing the 2 -1 subunit, leading in turn to reduced neurotransmitter release and attenuation of postsynaptic excitability [5] [6] [7] [8] [9] [10] • The decreased Ca 2+ influx reduces excitatory aminoacid (ex: glutamate) release leading to decreased AMPA receptor activation and noradrenaline relase in the brain [97] .
• Inhibitory modulation in neocortex, amygdale e hippocampus [21] .
Pharmacokinetics
• Available only as oral preparation.
• Absorption dependent by a saturable L-amino acid transport: the bioavailability of GBP varies inversely with dose: 300 mg= 60%; 600 mg= 40%; 1600 mg=35% (steady state).
• Plasma peak = 2.7-2.99 mg/l achieved 3-3.2 h after ingestion of 300 mg (because of the dose-dependent absorption, plasma peak increases less than threefold when the dose is tripled) • Volume of distribution: 0.6-0.8 l/Kg; cerebrospinal fluid concentration: 20% of plasma concentration; brain issue concentration: 80% the plasma level.
• No hepatic metabolism and it is eliminated unchanged in the urine with first order kinetic mechanism • Elimination half-life: 4.8-8.7 h.
• No microsomal enzyme induction. [90, 91, [98] [99] [100] • Available only as oral preparation.
• Absorption not saturable (linear pharmacokinetic profile) • Plasma peak (0.04-9.46 mg/L) reached in within 1 h.
• Average bioavailability> 90% independent of dose.
• Elimination half-life: 5.5-6.7h (independent of dose).
• No hepatic metabolism and renal excreted (98% unchanged in urine, 0.9%N-methylated derivative); elimination proportional to creatinine clearance. [92, 93, 101] 
Interactions
• No pharmacokinetic interaction with anticonvulsivant drugs [90] • Cimetidine decrease clearance of GBP (because decrease glomerular filtration) of 12% [90] • Antacids reduce bioavailability of GBP when given until 2h post its administration [102] .
• No pharmacokinetic interactions • Concurrent intake reduces peak plasma levels by 25-30% and increases the time to peak by 3 hours [92, 93, 101] limb pain the opinions are inconclusive. Bone et al. reported that GBP was efficacious to treat this syndrome [24] in discordance with other authors [25, 26] . GBP has been used also for attenuating haemodynamic response to tracheal intubation [27, 28] and on reducing postoperative delirium [28] , and like an alternative to benzodiazepines in the treatment of alcohol withdrawal [29] .
The first published PGL randomised clinical trials (RCTs) in 2001 [30] , and the first published GBP RCTs in 2002 [31, 32] reported cheering results for the treatment of the post-operative pain. The following years, several authors reported their experiences regarding the use of GBP and PGL [69] [70] [71] [72] [73] [74] [75] [76] for the post-operative pain management.
The main objective of this review is focusing the attention on the recent evidences for the analgesic properties and the adverse effects of GBP and PGL as treatment for the post-operative pain.
METHODS

The Selection of the Studies
The articles research was performed using MEDLINE, Cochrane Controlled Trials Register (CCTR), EMBASE, and CINAHL databases. Reference lists of the retrieved articles were also searched. The period of publication were established from 1990 to 2009. The first studies of PGL use after major surgery pain management were published in 2006 and furthermore previous systematic narrative [11, 28, 77, 78] or meta-analytic [79] [80] [81] [82] [83] [84] [85] reviews reported data from GBP clinical trials until 2006 (included). A total of three trials on PGL use for post-operative pain management [30, 69, 71] have been included in only one review [11] and the other three [77] [78] [79] included only one trial on postoperative dental pain published in 2001 [30] . Thus, we decided to take in consideration only recent (from 2006-2009) RCTs which investigated the analgesic effects of GBP or PGL in adult patients (age range 18 years and above) underwent to surgical procedures. Trials were included if they were randomized, double-blind, active or placebo controlled, had at least 10 subjects per study group, and reported both analgesic consumption and pain scores. Trials studying both pre and post -operative GBP or PGL were included, also if these drugs were part of a multimodal technique. Works that reported information about use of GBP and PGL in different settings (treatment of epilepsy, neuropathic pain, and other type of pain or that produced by other drugs), nonrandomised or experimental pain studies, case reports, and clinical observations and editorials were excluded. No language restrictions were applied and no investigators were contacted. Abstracts published in congresses acts and unpublished studies were not considered. The following search terms were included: gabapentin; pregabalin; postoperative pain; postoperative analgesia; pain measurement; postoperative nausea and vomiting; postoperative outcome. The reference lists of the selected studies and reviews were checked for additional citations. The last search was performed on 30 April 2009.
Literature Information, Outcome Measures
The following information were collected: 1) publication details, 2) patient population, number of patients, age, sex (male/female), settings and surgical procedure, 3) study design, description of drugs administration and follow-up, 5) intra-and postoperative analgesics and type of administration, 6) outcome measures, pain and analgesic consumption, 7) withdrawals and adverse effects. Bibliographic research was performed and data were collected independently by three investigators (S. F, L. C, R. C) and reviewed by the others (M. D, A. G., AF. S). In order to measure the likelyhood of bias in pain research reports, the Jadad score calculation was performed for each of clinical trials included in the review ( Table 2 ) [86] .
RESULTS
Post-surgical Pain
At the time of writing, we found an overall of 50 original works that reported the gabapentinoids use in 4248 surgical patients [87] [88] [89] . Nine of them studied the effects of PGL [30, [69] [70] [71] [72] [73] [74] [75] [76] and the other 41 those of gabapentin [87] [88] [89] in different surgical settings as gynaecological, abdominal, neurosurgery, musculoskeletal, thoracic, head, neck and breast. Gabapentin studies involved totally 3343 patients, 1514 of them received gabapentin and were confronted with 282 patients who received combination of [79] [80] [81] [82] [83] [84] [85] .
Gabapentin RCTs
Three of the 25 gabapentin studies were not RCTs [87] [88] [89] . Nissman's et al. work was a prospective cohort study that included a total of 141 patients and reported information about analgesic properties of gabapentin after keratectomy [88] , meanwhile Parsa et al. analyzed the gabapentin and celecoxib combination in aesthetic surgery (118 patients) [89] . In all these works the results were then compared with previous data as control patients concluding that gabapentin administration significantly reduces postoperative pain and opioid requirements. Van Elstraete, found that the median effective dose of pre-emptive gabapentin on postoperative morphine consumption after posterior lumbar spinal fusion was 21.7 mg kg -1 (95%CI: 19.9 -23.5 mg kg -1 ) [87] . More detailed information regarding each of 22 gabapentin RCTs (an overall of 1640 patients) included in the review is reported in Table 3 . There has been tested a large modality of GBP administration for post-surgical analgesia. All the RCTs administered pre-emptive gabapentin or its combination with other analgesic drugs. Thirteen of all presented RCTs evaluated pre (10 RCTs) [50, 52, 54, 56, 58, 61, 63, 64, 67, 68] and both pre/post-operative (3 RCTs) [48, 49, 59 ] doses of GBP alone vs placebo patients. Eight RCTs studied gabapentin in confront with other analgesics (dexamethasone, lornoxicam, celecoxib, rofecoxib, acetaminophen, clonidine); five of them used only pre-emptive analgesia [53, 55, 57, 62, 65 ] and 3 considered both pre and post-operative mixture administration [47, 51, 66] . Only one work confronted different dosages of pre-emptive gabapentin, concluding that increasing the dose of gabapentin (300 to 1200 mg), appears to significantly decrease the severity of postoperative pain and total fentanyl consumption during the first 24 hours after myomectomy [60] . Variable GBP preemptive doses from 300 mg to 1600 mg were administered achieving the highest dosage of 3200 mg/day at the surgery day in one RCT [59] . No studies considered the comparison of pre-emptive and post-incisional or post-surgery GBP administration. The follow up period was no more than 24 h in thirteen studies [50, nine studies the patients' observation varied from 2 to 7 POD [47-49, 51, 52, 59, 64-66] , and four of them inter-viewed the patients by phone also one month [48, 59, 66] and three month [47] post-surgery. No studies established the optimal post surgical GBP treatment duration. Pain assessment has been performed using a Visual Analogue Scale (VAS) in 18 RCTs [48, 50, [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] , meanwhile three studies used a 11-point [47, 49] or 4-point [51] Verbal Rating Scale (VRS). One study did not consider pain evaluation but only postoperative PCA fentanyl consump-tion, focusing the attention to the anti-emetic gabapentin effects [68] . One study assessed the pain only at rest [56] , eleven RCTs evaluated pain both at rest and on movement [48, 50, 51, 53, 55, 58, 59, 61, 63, 64, 66] and the remaining 9 works did not specify whether pain was measured at rest or with movement [47, 49, 52, 54, 57, 60, 62, 65, 67] . The total rescue analgesics consumption has been used as another outcome for the assessment of the post-operative analgesia efficacy. In nine works the patients have been instructed to use an i.v. PCA pump with morphine [47, 48, 53, 55, 59, 62, 65] or fentanyl [64, 68] without continuous infusion. Seven studies reported i.v. morphine [50, 52, 56] or fentanyl [54, 60, 66, 67] boluses on demand administered by the personnel. Two RCTs used an epidural PCA pump with [61] or without continuous anaesthetic infusion [49] . Other rescue analgesics have been administered on demand in 13 studies that was alone [51, 57, 58, 63] or in adjunction to the previous i.v. opioid boluses [47, 48, 52, 54, 59, 64, 66] or epidural PCA [49, 61] . Furthermore, three RCTs have treated all the patients with a standard analgesic regimen as well as the on demand therapy [51, 52, 64] . Three studies [52, 54, 56] registered also the time elapsed from the end of the surgery to the first analgesic demand as a further outcome. Higher morphine consumption in group C vs A and B (p<0.05), and higher morphine consumption in group A vs B (p<0.05) at all time points. Higher VAS scores at rest and at movement at all time points in group C vs A and B (p<0.05). SpO2 at 24 h was lower in group C vs A and B (p<0.05). Lower sedation in group C vs A and B until 4 h (p<0.05). Higher sedation in group C vs A and B at 24 h, the difference was only statistically significant for group B (p<0.05). At all time points, the patient dissatisfaction scores were higher in group C vs groups A and B (p<0.05). No significant difference in terms of the side-effects. Groups were similar regarding: VAS values at rest and after cough, p=NS, nausea or vomiting, dizziness, and sedation during all the point time follow up. Number of patients who required analgesics at home the first month after surgery did not differ between the two groups, P=NS. Overall cumulative morphine consumption at 48h, group A: 31.6±13.2 mg vs group B: 50.6±20.5 mg, p<0.001. During the postoperative days 3-7, the group A consumed fewer acetaminophen-codeine than group B, p=0.011. Fewer patients experienced pain 1 month after surgery in group A vs group B, P=0.045). 
Said-Ahmed 2007
Setting
Anaesthesia:
general anaesthesia and trocar insertion sites were infiltrated with up to 15 mL of 0.25% bupivacaine.
Intraoperative:
IV fentanyl 2-5 g·kg
Post-operative: IV fentanyl 12.5-25 g every 3 min as needed. Upon discharge from hospital, patients were prescribed either codeine 30-60 mg or morphine 5-10 mg PO every 3 h as needed.
Lower rest pain at 60 min in the group B vs A (p=0.003). Pain decreased from 60 to 120 min (p=0.0005, 0.005, <0.0001 for pain evoked by peak expiration, sitting, and cough, respectively), but no differences between groups (p=0.7, 0.3, 0.3, and 0.08 for shoulder pain, pain evoked by peak expiration, sitting, and cough pain, respectively).
Lower cough pain at 60 min in the group B vs A (p=0.01). On POD 1, 2, and 30, no differences between groups on pain. No differences among groups in opioid consumption until POD 3. No significant effect of treatment by time interaction for any of the spirometric measures (p=0.44, 0.07, and 0.35 for PEF, FEV1, and FVC, respectively). All spirometric measures improved from 60 to 120 min (p<0.0003), but groups were not different for PEF, FEV1, and FVC (p=0.3, 0.9, 0.9, respectively). PEF was higher in group C vs A at 120 min (p=0.02). Less nausea in the group C vs A (p=0.016) but not vs B (p=0.8). Median time (hours) from PACU admission to meeting PACU discharge criteria was 2.92, 2.83, and 2.75 for group A, B and C, respectively (p=NS). Mean time (days) from surgery to return to work was 13.6, 11.7, and 10.6 for groups A, B, and C respectively (p=NS).
( at induction than boluses of 5-10 g Post-operative: IV acetaminophen 1 g or 50 mg IV tramadol.
The total (median, range) analgesic consumption (paracetamol and tramadol) was 3 (0 -5) in group A vs 3 (1-5) in B, p=NS. Tramadol was required in 27.3% patients in group A vs 23.5% in B (p=NS). No significant differences between groups for VAS at rest and during swallowing. After 6 mo, 8 patients presented pain scores < 3 vs 2 patients in the preoperative period (p=0.04). It was significantly lower in group A. There was a trend toward greater burning sensation and numbness in group B, but p=NS. GBP provided better post-operative analgesia and rescue analgesics sparing than placebo in 6 of the 10 RCTs that administered only pre-emptive analgesia [50, 54, 56, 58, 64, 67, 68] . Three studies reported no GBP effects on pain No statistically significant differences in the VAS score. Cumulative use of supplement analgesics was similar in each group (group A: 6±3, B: 7±3 tablets). Time to the use of the first analgesic tablet was comparable in the two groups (group A: 768 ± 218 min vs B: 719±199 min). Side effects were comparable in both groups, except that headaches were more frequent in the group B (P=0.034). About 25%-30% of the patients considered their analgesia insufficient. However, scores for overall satisfaction were high (about 80 mm in both groups) and did not differ between the two groups.
Jeon, 2008
Turan, 2007
Setting tourniquet pain and I.V. regional anesthesia. GBP -gabapentin; PL -placebo; VAS -Visual Analogue Scale; I.V. -intravenous; POD -post-operative day; PCA -patient controlled analgesia; PCEA -patient controlled epidural analgesia; HR -heart rate; MAP -mean arterial pressure; AUC-area under the curve scores or rescue analgesics sparing [52, 61, 63] . One study that did not assessed pain reported only opioid sparing effect of GBP [68] . Of the 5 RCTs that measured pain with movement, 3 demonstrated significantly reduced movementrelated pain in GBP patients [50, 58, 64] . Three RCTs compared pre and post-operative GBP administration with placebo. Turan at al found perioperative GBP treatment useful for pain reduction and epidural PCA solution sparing and oral acetaminophen reduction [49] . Fassoulaki et al. did not demonstrate any benefits in early pain management and analgesics sparing with perioperative gabapentin after hysterectomy [48] . The same authors reported opioid sparing but not pain reduction, in the same setting the following year [59] . However, in both works they found a significant pain reduction one month after surgery [48, 59] . Several RCTs compared GBP with other analgesics for post-operative pain management. In adjunction to dexamethasone [57] or to a selective COX-2 inhibitor as rofecoxib [47, 51] or lornoxicam [53] GBP did not seem to offer further benefits on pain management in comparison with GBP, dexamethasone, rofecoxib or lornoxicam alone. However, there were reported reduced intra [57] and post surgery [51, 57] analgesics consumption or number of patients requesting analgesics [53] . Meanwhile, Gilron et al. did not find substantial positive effects of GBP-meloxicam mixture with those of GBP and meloxicam alone on pain control and opioid sparing after laparoscopic colecystectomy [66] . Mohammadi et al. described positive GBP effects on reduction of pain and PCA morphine consumption when compared with clonidine after abdominal and pelvic surgery [62] , but their assertions where not confirmed by Ghafari et al. after laparoscopic gynaecological surgery [65] . GBPacetaminophen combination provides better pain control and reduced PCA-morphine consumption in comparison with GBP alone or placebo after abdominal hysterectomy [55] . Different dosages of gabapentin have been confronted only by Said-Ahmed that reported increasing the pre-emptive dose of gabapentin (300 to 1200 mg), significantly decrease the severity of post-myomectomy pain and total opioid consumption during the first 24 hours after surgery [60] . Two of the 3 trials that evaluated the time elapsed from the end of surgery to the first analgesic request, reported that it was significantly longer in GBP group vs placebo [54, 56] but the other one did not find difference [52] .
Related to a specific antiemetic effect, 14 RCTs suggested that GBP did not reduce nausea and vomiting following surgery when compared with placebo [49, 50, 52, 54, 56, 58, 59, 61, 63, 64, 67] . clonidine [62, 65] , or lornoxicam [53] . Three RCTs that studied the gabapentin alone [68] or its combination with dexamethasone [57] or rofecoxib [47] reported a significant reduction of PONV in gabapentin patients vs placebo [47, 57, 68] . Furthermore, GBP-dexamethasone combination seems to have a synergic positive effect on PONV reduction in confront with GBP or dexamethasone alone [57] . Combined with COX-2 inhibitors, GBP seems to have similar incidence of PONV where confronted with GBP [47, 66] and rofecoxib [47] alone and less if confronted with meloxicam alone [66] . These findings are in contradiction with those of Mikkelsen at al who reported five-fold more incidence of PONV in GBP-rofecoxib group than rofecoxib alone group [51] . Gilron et al. demonstrated that there are not differences on lung function during treatment with either GBP, meloxicam or both after laparoscopic cholecystectomy as assessed by peak expiratory flow rate [66] . This findings are in contradiction with a previous work of the same authors where these improvements were enhanced even further when GBP was combined with another COX-2 inhibitor for abdominal hysterectomy [41] . Furthermore, they were not able to demonstrate benefits of gabapentin on PACU discharge and return to work [66] . The most frequent other adverse effects were sedation, dizziness, headache. No statistical differences regarding the adverse effects have been observed between GBP, other analgesics, combination or placebo in 17 RCTs [47, 50, 53, [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] . Two studies reported less headache in gabapentin group [52, 54] and other two trials found more dizziness with GBP administration [49, 51] . Meanwhile, Fassoulaki et al. excluded the patients having PONV or other side effects from the study [48] .
Pregabalin RCTs
More detailed information regarding each of the eight PGL RCTs (an overall of 707 patients) included in the review is reported in Table 4 . There has been tested a large modality of PGL administration for post-surgical analgesia. All the RCTs administered pre-emptive PGL or its combination with other analgesic drugs. Three RCTs evaluated pre [70, 75] and both pre/post-operative [73] PGL alone vs placebo patients. The PGL -other analgesic [dexamethasone [74] , ibuprofen [72] , celecoxib [69] , and both acetaminophen-dexamethasone [76] , combination has been studied by four RCTs, three of them used only preemptive analgesia [72, 74, 76] and one considered a second 12 h post-operative administration of the same pre-emptive drugs [69] . Totally, three different PGL pre-emptive dosages (75 mg, 150 mg and 300 mg) have been studied. Jokela et al. confronted different dosages (300 mg and 600 mg) of perioperative of PGL alone with diazepam 10 mg as control group after laparoscopic hysterectomy concluding that only PGL 600 mg, decreases oxycodone consumption postoperatively, and is associated with an increased incidence of dizziness, blurred vision, and headache [71] . However, when the same authors tested the pre-emptive PGL 150 or 75 mg in combination with ibuprofen in a similar setting, they did not found differences about neither the amount of postoperative analgesics required, nor the incidence of sideeffects [72] . No studies considered the comparison of preemptive and post-incisional or post-surgery PGL administration. The follow up period was no more than 24 h in 6 RCTs [69, 70, 72, 74, 75, 76] , one trial followed the patients for 72 hours [71] and the the other once a day till 7 POD [73] . No studies established the optimal post surgical PGL treatment duration. Five studies assessed pain by using VAS [71, 72, [74] [75] [76] , one study used both VAS and 4-point VRS [70] , and the other two used an 11-point VRS [69, 73] . Six RCTs evaluated pain both at rest and on movement [69, 70, 72, [74] [75] [76] and the remaining 2 works did not specify whether pain was measured at rest or with movement [71, 73] . All the PGL-studies used the total rescue analgesics consumption as an important outcome for testing post-operative analgesia level. Morphine was delivered by the patients instructed to use an i.v. PCA pump in three RCTs [69, 74, 76] , fentanyl [75] or oxycodone [71] in one trial respectively, without continuous infusion. The other studies reported administration of fentanyl [70, 72] or hydrocodone [73] as needed. In adjunction to the i.v. opioid boluses other rescue analgesics have been administered on demand in 3 studies [70] [71] [72] . Furthermore, four RCTs have treated all the patients with a standard analgesic regimen as well as the on demand therapy [71, 72, 74, 76] . Two RCTs registered the time elapsed from the end of the surgery to the firs analgesic demand as a further outcome [72, 73] . The groups were similar regarding: the patients' score (0-10) for anxiety; the times to the first rescue fentanyl dose, the doses of fentanyl in the RR; and the number of patients taking acetaminophen-codeine. The AUC values for VAS at rest 1-8 h after surgery (P=0.048) and in motion (P=0.046) were lower in the group B than in the group C. The AUC values for VAS at cough, the degree of drowsiness, the incidence of side effects, the patients' satisfaction with anaesthesia and pain management did not differ in the three groups. PGL provided better post-operative analgesia and rescue analgesics sparing than placebo in two [73, 75] of the three RCTs [70, 73, 75] that evaluated the effects of PGL alone vs placebo. The other one [73] did not find any differences between PGL and placebo on VAS and PCA opioid consumption. Mathiesen et al. studied the triple combination of 300 mg of PGL with dexamethasone and acetaminophen and did not find VAS reduction in confront of PGLacetaminophen and acetaminophen alone after hip arthroplasty [74] and hysterectomy [76] . The post-surgery morphine consumption was similar in groups after hysterectomy [76] but higher in acetaminophen patients than PGL-acetaminophen and PGL-dexamethasone-acetaminophen patients after total hip arthroplasty [74] . Jokela et al. did not demonstrate VAS differences during all the 24 h post-hysterectomy follow up period between peri-operative administration of 300 mg or 600 mg of PGL and 10 mg of diazepam as control group [71] . The overall oxycodone consumption was lower in 600 mg PGL group vs 300 mg PGL group at 12-24 h period and in PGL 300 mg group vs diazepam at 24 h after surgery [71] . In adjunction to ibuprofen and diazepam, 150 mg of PGL provides better analgesia than PGL 75 mg-ibuprofen-diazepam and ibuprofen-diazepam association, but the rescue analgesic consumption was similar between groups [72] . No differences regarding the time elapsed from the end of the surgery and the first analgesic request has been observed both above-mentioned RCTs [71, 72] .Reuben at al reported as the peri-operative PGL-rofecoxib association reduced pain and opioid consumption regarding PGL or rofecoxib alone, after spinal fusion surgery [69] . Four studies reported no PGL effects on preventing the PONV [70] [71] [72] 75] . Mathiesen et al. [74] and Freedman et al. [73] findings suggest that PGL administration increases the incidence of PONV, meanwhile two other trials reported a reduction of PONV in PGL patients [69, 76] . PGL caused significantly more other (Table 4) side effects than placebo in two trials [70, 71] . In other two RCTs the adverse effects in patients who received PGL were similar with those of the other groups [72, 75, 76] . Mathiesen et al. reported more sedation in PGL-acetaminophen group in confront of PGL-dexamethasone-acetaminophen combination and acetaminophen alone [74] . Meanwhile Reuben et al. findings suggested that PGL receiving patients reported higher incidence of sedation vs patients who received the combination of PGL-rofecoxib or rofecoxib alone [69] . Freedman et al. did not report data about side effects [73] .
Anaesthesia
Meta-analysis
An overall of 7 meta-analysis regarding gabapentin use for apost-operative pain management [79] [80] [81] [82] [83] [84] [85] has been included in this review and the most important data of these studies are reported in the Table 5 . All these works findings are in accordance each other regarding the analgesic effects of GBP on the post operative setting. Statistically significant reduction of pain and rescue analgesic consumption has been reported by all the meta-analysis with GBP administration vs placebo during the perioperative period [79] [80] [81] [82] [83] [84] [85] . The most studied adverse effects were nausea and/or vomiting, sedation and dizziness. GBP effects on PONV reduction are not conclusive. Both Hurley et al. [81] and Seib et al. [83] did not find statistically significant difference with GBP administration with respect to reduction of incidence of PONV, in discordance with the other authors who described a significant reduction of nausea and vomiting [79, 80, 82, 84, 85] . The GBP-related sedation is reported in 5 of the 7 meta-analysis [79] [80] [81] [82] 84] . The other two authors did not find any increase of the sedation incidence associated with GBP administration [83, 85] . More dizziness has been described by three authors in GBP patients [84, 79, 82] in discordance with Hurley et al. [81] who did not find any difference.
DISCUSSION
Both past and recent evidences (included in this review) with respect to the benefits of GBP/PGL administration for post-operative pain management are generally in favour of these drugs when confronted with placebo. Especially, due to the large number of the RCTs currently available, the GBP vs placebo efficacy on pain reduction and opioid sparing is clear. However, the meta-analysis included in the Table 5 Lower opioid consumption (P < 0.05) in the GBP treatment arm (WMD 13.7; 95% CI 8.9-18.5).
The incidence of GBP-related side effects (dizziness, light headedness, visual disturbance and headache) was similar in the GBP and control groups. There were no significant differences with respect to the incidence of opioid related adverse effects (nausea, vomiting, sedation, constipation, urinary retention, pruritus, and respiratory depression) between the GBP and control groups.
Preoperative GBP is effective in reducing postoperative opioid consumption in the first 24 hr after surgery and the pain scores a rest and with mobilization. Doses of 1200 mg are more effective in reducing analgesic consumption than doses of 300 or 400 mg. GBP treatment did not reduce the incidence of opioid related side effects. Perioperative oral GBP appears to be a useful adjunct for the postoperative analgesia through a different mechanism than other available analgesic agents. As a part of a multimodal treatment plan, GBP may provide synergistic analgesic effects with other agents.
( GBP dosages from 300 to 1200 mg. In the PGL study the dose was 50 or 300 mg. Thirteen of the studies were single-dose trials and 9 with multiple dosing of GBP or PGL.
There was wide variation in pain at rest after different types of surgery. The overall VAS pain difference between GBP and control groups ranged from 5 mm to 35 mm during the first 12 h post surgery and from 0 mm to 28 mm during 12h-24 h post-surgery. The opioid-sparing effect during the first 24 h after a single preoperative dose of GBP 300-1200 mg, administered 1-2 h before surgery, ranged from 20% to 62%, (WMD -2.0, 95% CI: -2.5, -1.4). The combined effect of a single dose of GBP on opioid consumption was equivalent to reduction of 30 ± 4 mg of morphine consumed during the first 24 h after the surgery. Heterogeneity among the studies was significant (P<0.0001). The NNT to prevent nausea, vomiting, or urinary retention were 25, 6, and 7, respectively. The NNH for GBP to produce excessive sedation or dizziness were 35 and 12, respectively. There were no significant differences in any other adverse effects.
GBP is effective in reducing pain intensity, opioid consumption and opioid-related adverse effects after surgery. It has very few adverse effects. Because of the heterogeneous data of these studies, no conclusions about the optimal dose and duration of the treatment can be drawn.
McQuay, 2008
18 RCTs,
Reference 82
Outcome measures Pain scores, analgesic consumption, and side effects. Trials with similar pain scores between the groups within a predetermined time interval were classified as category A and those reporting different pain scores between the groups within the same time period as category B.
Patients included
A total of 1217 patients. GBP dosages from 300 to 1200 mg. All trials used a placebo, except one using oxazepam. All trials, except one, administered one or more doses of GBP before operation, 5 of these continued GBP after operation.
In Category A trials, the pain scores in the placebo groups at 4 h were all 30/100 mm VAS or equivalent. This was achieved even though baseline pain scores were greater than 30/100 mm with one exception. This may reflect an effective analgesic delivery system, which a valid analgesic consumption outcome measure should have. Most Category B trials failed to achieve a similar reduction in pain score at 4 h. In some trials, it was not achieved even at later time points, and this may reflect a failing of analgesic delivery. This suggests that Category B trials were less robust than category A. Of the seven category A trials, four reported reduced analgesic consumption with GBP compared with placebo at one or more time points and three trials reported no difference between GBP and placebo. The weighted mean analgesic consumption for GBP compared with placebo (24 h where available, or longest time) was 71% in Category A trials. All 11 Category B trials reported a decrease in analgesic consumption with GBP at one or more time points. The weighted mean analgesic consumption of GBP compared with placebo was 59% for Category B trials. Combining all 18 trials, the weighted mean consumption was 62%, a reduction in analgesic consumption in the GBP group of 38%. There were a statistically significant increase in the incidence of sedation (RR, 2.2; 95%CI: 1.7-3.0) and dizziness (RR, 1.6; 95%CI: 1.1-2.2) and a statistically significant decrease in the incidence of vomiting (RR, 0.7; 95%CI: 0.5-0.9) but not nausea with GBP compared with control group. Nevertheless, a large number of published placebocontrolled, double-blind, randomized trials have demonstrated the postoperative analgesic efficacy with GBP and PGL, the RCTs that take in consideration gabapentinoids' analgesic and opioid-sparing efficacy with respect to other analgesic drugs are very heterogeneous [47, 51, 53, 55, 57, 62, 65, 66, 69, 70, 72, 74, 76] . Gabapentinoids are perhaps superior to celecoxib [69] and meloxicam [66] and border line with respect to lornoxicam [53] . Gilron et al. in a study published in 2005 described as GBP and rofecoxib provided better analgesia than either single agent and also PCA-morphine consumption is more reduced with GBProfecoxib treatment [41] . Studying GBP-rofecoxib association, Mikkelsen et al. found only opioid sparing effects in confront of rofecoxib alone [51] in discordance with Turan et al. results who did not report substantial differences between GBP-rofecoxib combination and rofecoxib or GBP alone with respect to VAS reduction and opioids sparing [47] . Meanwhile, in confront with clonidine, GBP is more efficacious as Mohammadi et al. [62] or similar as Ghafari et al. findings [65] . GBP-acetaminophen was more effective than GBP alone with respect to overall opioid consumption and on VAS reduction till 4 h post-surgery, however the groups were than similar for each other during the remaining follow up period [55] . No more data that tested this combination are available at the moment. The gabapentinoids-dexamethasone association did not offer further benefits on VAS reduction in confront of GBP [57] , acetaminophen [74, 76] , or dexamethasone alone [57] and a significant opioid sparing has been reached only in one of these three studies [57] . No other RCTs that studied this kind of combination are available in the literature at the best of our knowledge.
The optimal dose of the gabapentinoids for the postoperative pain management is not clear. Said-Ahmed reported that increasing the pre-emptive dose of gabapentin (300 to 1200 mg), significantly decrease the severity of postmyomectomy pain and total opioid consumption during the first 24 hours after surgery [60] . These findings are in discordance with Pandey et al. results after lumbar discectomy setting, published on 2005, that demonstrated pain reduction with 600mg was better than with 300 mg but no additional benefits were observed at doses of 900 or 1200mg [44] . However, further work is needed to better define the optimal GBP dose for specific surgical procedures.
The GBP Elimination half-life is 4.8-8.7 h [90, 91] and the PGL elimination half-life is 5.5-6.7h [92, 93] . The likely time during which the clinical effect of GBP/PGL should be maximally present is 4-12 h after surgery. Beyond 24 h, no residual effect of single dose GBP was expected. as confirmed by several authors who administered only preemptive GBP/PGL did not find analgesic or opioid sparing effects over than 24 h [47, 64, 65, 71] . However, Fassoulaki et al. in two different studies [48, 59] found analgesic benefits after peri-operative GBP administration 1 month after surgery. A possible answer could be that treating acute postoperative pain preoperatively may prevent or attenuate persistent postsurgical pain [94] but further investigation are needed to elucidate this aspect.
The mechanism of gabapentin in the prevention of PONV is unknown but it could possibly be due to the indirect effect of opioid sparing or a direct effect on tachykinin activity [95] . Two RCTs published in 2004 are discordant about GBP effects on PONV. Pandey et al. reported more sedation and nausea [34] , whereas Turan et al. reported less nausea/vomiting and less urinary retention with gabapentin [39] . The majority of the RCTs that considered a direct gabapentinoids-placebo-confront (18 of 24) reported GBP improves the analgesic efficacy of opioids at rest and with movement, reduces analgesic consumption and reduces opioidrelated adverse events. However, it is also associated with an increased risk of dizziness and sedation.
GBP -gabapentin; PGL -pregabalin; RCTs -randomised clinical trials; WMD -weighted mean difference; NNT -numbers-needed-to-treat; NNH -numbers-needed-to-harm; RRrelative risk; 95%CI -95% confidence interval opioid-sparing effects with GBP or PGL administration vs placebo. However, only two of these trials reported a concurrent reduction in opioid-related nausea or vomiting in GPB-alone group vs placebo group [57, 68] . Due to the wellknown antiemetic effect of dexamethasone [104] [96] when it was administered in combination with GBP a significant PONV reduction has been reported [57, 74] . Turan et al. reported as the highest morphine sparing effect was achieved in GBP-rofecoxib group registering also the lowest PONV incidence in those patients after hysterectomy [47] . Two studies reported higher incidence of PONV with GBP [51] or PGL [71] administration. Generally our data on PONV incidence are in accordance with those of Seib et al. [83] and Hurley et al. [81] meta-analysis and in discordance with the other authors who described a significant reduction of nausea and vomiting [79, 80, 82, 84, 85] . Meanwhile, the information reported from the other systematic-narrative reviews regarding PONV are inconclusive [11, 28, 77, 78] Furthermore, it would be considered that RCTs included in the previous reviews and those included in the present one are partially different.
CONCLUSION
In conclusion, gabapentin and pregabalin are effective in reducing pain intensity and opioid consumption after surgery in confront with placebo. The analgesic potentials of gabapentinoids in comparison with other standard postoperative regimens are still not clear. There are not exhaustive evidences about the optimal dose and duration of the post-operative treatment with GBP/PGL. Since only a little number of RCTs has followed the patients for a long post-operative period, the efficacy of gabapentinoids in preventing chronic post-operative pain needs to be elucidated in future studies. Gabapentin and pregabalin seem not to have any influence on the prevention of post-operative nausea and vomiting.
